Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

In this cohort of patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use was associated with significantly lower risks of vertebral compression fractures and related ...

In 2025, the line between brand messaging and cultural commentary continued to blur. As the year ends, let’s look back at the ...

The study analyzed electronic health records from 708,406 patients diagnosed with breast cancer between January 2011 and ...

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk ...

WHO outlines first-ever global recommendations for GLP-1 medicines in obesity care, stressing long-term use and behavioural support ...

In public health and in clinical practice, terms matter. Not because they change the biology, but because they shape how ...